{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:48:22Z","timestamp":1789069702568,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00467-026-07268-9","type":"journal-article","created":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T03:51:41Z","timestamp":1774151501000},"page":"2767-2773","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A pediatric case of C3 glomerulonephritis initially misclassified as IgA nephropathy with a favorable response to C3-targeted therapy"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-0307","authenticated-orcid":false,"given":"Laura F.","family":"Alconcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anal\u00eda","family":"S\u00e1nchez Lucero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Fernanda","family":"Toniolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,22]]},"reference":[{"key":"7268_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","volume":"15","author":"RJH Smith","year":"2019","unstructured":"Smith RJH, Appel GB, Blom AM et al (2019) C3 glomerulopathy-understanding a rare complement-driven renal disease. Nat Rev Nephrol 15:129\u2013143. https:\/\/doi.org\/10.1038\/s41581-018-0107-2","journal-title":"Nat Rev Nephrol"},{"key":"7268_CR2","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/ndt\/gfae245","volume":"40","author":"MS Meuleman","year":"2025","unstructured":"Meuleman MS, Roquigny J, Brousse R et al (2025) Acquired and genetic determinants of disease phenotype and therapeutic strategies in C3 glomerulopathy and immunoglobulin-associated MPGN. Nephrol Dial Transplant 40:842\u2013851. https:\/\/doi.org\/10.1093\/ndt\/gfae245","journal-title":"Nephrol Dial Transplant"},{"key":"7268_CR3","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Caster DJ, Cattran DC et al (2021) Executive summary of the KDIGO guideline for the management of glomerular diseases. Kidney Int 100:753\u2013779. https:\/\/doi.org\/10.1016\/j.kint.2021.05.015","journal-title":"Kidney Int"},{"key":"7268_CR4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/ki.2012.384","volume":"83","author":"S Sethi","year":"2013","unstructured":"Sethi S, Fervenza FC, Zhang Y, Zand L et al (2013) Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int 83:293\u2013299. https:\/\/doi.org\/10.1038\/ki.2012.384","journal-title":"Kidney Int"},{"key":"7268_CR5","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/ajmg.c.31986","volume":"190","author":"AK Heiderscheit","year":"2022","unstructured":"Heiderscheit AK, Hauer JJ, Smith RJH (2022) C3 glomerulopathy: understanding an ultra-rare complement-mediated renal disease. Am J Med Genet C Semin Med Genet 190:344\u2013357. https:\/\/doi.org\/10.1002\/ajmg.c.31986","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"7268_CR6","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00467-022-05644-9","volume":"38","author":"M Mizerska-Wasiak","year":"2023","unstructured":"Mizerska-Wasiak M (2023) How to take advantage of easily available biomarkers in patients with IgA nephropathy: IgA and C3 in serum and kidney biopsy. Pediatr Nephrol 38:1439\u20131448. https:\/\/doi.org\/10.1007\/s00467-022-05644-9","journal-title":"Pediatr Nephrol"},{"key":"7268_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ekir.2025.10.020","volume":"11","author":"D Kavanagh","year":"2025","unstructured":"Kavanagh D, Ariceta G, Vivarelli M, Schaefer F, Caravaca-Font\u00e1n F et al (2025) Current and emerging therapies for C3 glomerulopathy and primary (idiopathic) immune complex membranoproliferative glomerulonephritis. Kidney Int Rep 11:17\u201331. https:\/\/doi.org\/10.1016\/j.ekir.2025.10.020","journal-title":"Kidney Int Rep"},{"key":"7268_CR8","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00467-024-06587-z","volume":"40","author":"A Cappoli","year":"2025","unstructured":"Cappoli A, Kersnik-Levart T, Silecchia V, Ariceta G et al (2025) C3 glomerulopathy in children: a longitudinal study evaluating outcome. Pediatr Nephrol 40:979\u2013986. https:\/\/doi.org\/10.1007\/s00467-024-06587-z","journal-title":"Pediatr Nephrol"},{"key":"7268_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2017.11.019","volume":"72","author":"M Le Quintrec","year":"2018","unstructured":"Le Quintrec M, Lapeyraque AL, Lionet A, Sellier-Leclerc AL et al (2018) Patterns of clinical response to eculizumab in patients with C3 glomerulopathy. Am J Kidney Dis 72:84\u201392. https:\/\/doi.org\/10.1053\/j.ajkd.2017.11.019","journal-title":"Am J Kidney Dis"},{"key":"7268_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-023-03058-9","volume":"24","author":"T Welte","year":"2023","unstructured":"Welte T, Arnold F, Westermann L, Rottmann FA et al (2023) Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study. BMC Nephrol 24:8. https:\/\/doi.org\/10.1186\/s12882-023-03058-9","journal-title":"BMC Nephrol"},{"issue":"6","key":"7268_CR11","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1053\/j.ajkd.2018.07.013","volume":"72","author":"C Duineveld","year":"2018","unstructured":"Duineveld C, van de Kar NCAJ, Wetzels JFM (2018) Benefit of eculizumab compared to standard of care still unproven in C3 glomerulopathy. Am J Kidney Dis 72:906. https:\/\/doi.org\/10.1053\/j.ajkd.2018.07.013","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 2","key":"7268_CR12","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.1016\/j.ekir.2024.11.300","volume":"10","author":"C Nester","year":"2025","unstructured":"Nester C, Smith R, Kavanagh D, Vivarelli M et al (2025) Efficacy and safety of iptacopan in patients with C3 glomerulopathy: 12-month results from the phase 3 APPEAR-C3G study. Kidney Int Rep 10(Suppl 2):S136\u2013S137. https:\/\/doi.org\/10.1016\/j.ekir.2024.11.300","journal-title":"Kidney Int Rep"},{"key":"7268_CR13","doi-asserted-by":"publisher","unstructured":"Nester CM, Bomback AS, Ariceta MG, Delmas Y et al (2024) VALIANT: a randomized, multicenter, double-blind, placebo-controlled Phase 3 trial of pegcetacoplan for patients with C3G or primary IC-MPGN. J Am Soc Nephrol 35(10 Suppl):SA-OR92. https:\/\/doi.org\/10.1681\/ASN.2024qdwvz5bg","DOI":"10.1681\/ASN.2024qdwvz5bg"},{"key":"7268_CR14","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1056\/NEJMoa2501510","volume":"393","author":"F Fakhouri","year":"2025","unstructured":"Fakhouri F, Bomback AS, Ariceta G, Delmas Y, Dixon BP, Gale DP, Greenbaum LA, Han SH, Isbel N, Le Quintrec M, Licht C, Mastrangelo A, Mizuno M, de Neves Holanda MI, Pickering MC, Remuzzi G, Van De Kar N, Vivarelli M, Walker PD, Wallace D, Zecher D, Francois C, Deschatelets P, Li L, Wang Z, Abad-Franch L, Kinnman N, L\u00f3pez-L\u00e1zaro L, Szamosi J, Nester CM, VALIANT Trial Investigators Group (2025) Trial of pegcetacoplan in C3 glomerulopathy and immune-complex MPGN. N Engl J Med 393:2210\u20132220. https:\/\/doi.org\/10.1056\/NEJMoa2501510","journal-title":"N Engl J Med"},{"key":"7268_CR15","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1007\/s00467-025-06673-w","volume":"40","author":"M Mancuso","year":"2025","unstructured":"Mancuso M, Cugno M, Griffini S, Grovetti E et al (2025) Efficacy of complement inhibition with pegcetacoplan in children with C3 glomerulopathy. Pediatr Nephrol 40:1959\u20131963. https:\/\/doi.org\/10.1007\/s00467-025-06673-w","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07268-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07268-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07268-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:06:11Z","timestamp":1785452771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-026-07268-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,22]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["7268"],"URL":"https:\/\/doi.org\/10.1007\/s00467-026-07268-9","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,22]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent for publication was obtained from the patient\u2019s parents\/legal guardians.","order":1,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}